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The hormone dependency of prostate cancer is well established and 
androgen receptor (AR) expression is frequently observed in primary 
prostate tumors and metastases (1). As a consequence, the development of 
radioligands that target the AR for prostate tumor imaging is an active area 
of research (2). The majority of these studies to date have focused on 
steroid-based ligands, including the naturally occurring androgens 
(testosterone, dihydrotestosterone) and synthetic steroids (mibolerone, 
metribolone) (3,4). 
The recent emergence of AR-selective, high-affinity, nonsteroidal 
antiandrogens such as RU 59063, (Table l), offers a usehl alternative 
approach towards AR radioligand development (5). Our goal in this study 
was to develop a suitable carbon-1 1 labeled nonsteroidal AR radioligand for 
PET imaging of prostate cancer. We recently showed that replacement of 
the trifluoromethyl group of RU 59063 with iodine (DTIB, Table 1) leads 
to a 3-fold enhancement in AR binding affinity (6). This observation led us 
to synthesize the N-methylated hydantoin and thiohydantoin derivatives 
(laJb),  which were subsequently shown to retain high affinity towards AR 
(Table 1). Since the synthesis of ["C]lJ by direct N-["C]methylation of 
its normethyl precursor is not feasible (due to preferential methylation on 
sulfur), the N-methyl derivative was selected for carbon-1 1 labeling. 
We report here the radiosynthesis of [ " C ] b  for evaluation as a AR 
radioligand for PET. 
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Table 1. Inhibition Constants (Ki) for Ligands at the Rat AR 
Figure 1' 
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a Reagents and conditions: (a) COC12, toluene, rt; (b) 2-arnino-2cyanopropane, Et3N. 
1.2-DCE. reflux; (c) 2 N HCI, CH30H, reflux; (d) 1. NaH 2. CH31; (e) 1. KF/Alurnina 2. "CH31. 
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A four step synthetic route starting from 4-cyano-3-iodoaniline 
provided in 37% overall yield (Figure 1). Radiosynthesis of ["C]& 
with ["C]CH31 was conducted in a microcolumn by a captive solvent 
method following adsorption of the normethyl precursor of on a solid 
phase mixture of 20% KF and 2% water in alumina. The labeled product 
was eluted with anhydrous ether through a column of basic alumina, 
concentrated, and dissolved in physiological sa1ine:EtOH (95:5) for animal 
studies. The radiochemical yield and specific activity of the product were 
45% (EOB) and >1300 Ci/mmole (EOS), respectively. 
In conclusion, a reliable and efficient synthesis of a carbon-1 1 labeled 
nonsteroidal androgen receptor ligand is reported. Biological studies are 
underway to determine the applicability of ["C]1_a as a PET radioligand for 
AR imaging. 
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